The Emerging Gait Dysfunction Phenotype in Idiopathic Parkinson’s Disease

Objective Severity of motor symptoms in Parkinson’s disease (PD), and rate of change of these symptoms, suggests the existence of disease subgroups. One important PD subgroup is defined by postural instability and gait dysfunction (PIGD), which is associated with disability, lower quality of life, and cognitive deterioration. In this study, we evaluate what clinical factors at baseline are associated with early development of postural instability in PD. Methods Data was downloaded from the Parkinson’s Progressive Markers Initiative (PPMI). Several clinical features predict development of postural instability. We provisionally term the associated phenotype the emerging gait disorder (eGD) phenotype. We evaluate validity of the phenotype in two held-out populations. Results Individuals with the proposed eGD phenotype have a significantly higher risk of developing postural instability in both validation sets (p < 0.00001 in both sets). The proposed eGD phenotype occurred before development of postural instability (HY stage ≥ 3) in 289 of 301 paired comparisons (Fischer Exact Test, p < 0.000001), with a median progression time from development of eGD phenotype to postural instability of 972 days. Individuals with the proposed eGD phenotype at baseline had more rapid cognitive decline as measured by the Montreal Cognitive Assessment (p = 0.002) and Hopkins Verbal Learning Test (Total Recall, p = 0.008). Interpretation We describe a clinical phenotype, detectable at baseline in a subset of individuals with PD, that is associated with accelerated development of postural instability. Within the sample, development of the eGD phenotype reliably precedes development of disability, and is a harbinger of more rapid cognitive progression.

[1]  R. Barker,et al.  The clinical heterogeneity of Parkinson's disease and its therapeutic implications , 2018, The European journal of neuroscience.

[2]  W. Au,et al.  Non‐motor symptoms in early Parkinson's disease with different motor subtypes and their associations with quality of life , 2018, European journal of neurology.

[3]  A. Singleton,et al.  Predicting progression in patients with Parkinson's disease , 2017, The Lancet Neurology.

[4]  Jeffrey M. Hausdorff,et al.  Do cognition and other non-motor symptoms decline similarly among patients with Parkinson’s disease motor subtypes? Findings from a 5-year prospective study , 2017, Journal of Neurology.

[5]  A. Tessitore,et al.  Cognitive impairment is associated with Hoehn and Yahr stages in early, de novo Parkinson disease patients. , 2017, Parkinsonism & related disorders.

[6]  C. Tanner,et al.  Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials , 2017, Movement disorders : official journal of the Movement Disorder Society.

[7]  C. Tanner,et al.  How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort? , 2016, Parkinsonism & related disorders.

[8]  C. Ritchie,et al.  A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease , 2016, BMC Neurology.

[9]  H. Shang,et al.  Non‐motor symptoms and quality of life in tremor dominant vs postural instability gait disorder Parkinson′s disease patients , 2016, Acta neurologica Scandinavica.

[10]  Giuseppe Orefice,et al.  The Heterogeneity of Early Parkinson’s Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients , 2013, PloS one.

[11]  J. Jankovic,et al.  How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale , 2013, Movement disorders : official journal of the Movement Disorder Society.

[12]  J. Massano,et al.  Cognitive Impairment and Dementia in Parkinson’s Disease: Clinical Features, Diagnosis, and Management , 2012, Front. Neur..

[13]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[14]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[15]  Bart Post,et al.  UvA-DARE ( Digital Academic Repository ) Clinimetrics , clinical profile and prognosis in early Parkinson ’ s disease , 2009 .

[16]  Nobutaka Hattori,et al.  Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations , 2006, Movement disorders : official journal of the Movement Disorder Society.

[17]  D. Aarsland,et al.  Changes in motor subtype and risk for incident dementia in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[18]  I. McKeith,et al.  Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  W. Poewe,et al.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[20]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[21]  C. Clarke A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs? , 2004, Movement disorders : official journal of the Movement Disorder Society.

[22]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[23]  Hansjürgen Bratzke,et al.  Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) , 2002, Journal of Neurology.

[24]  Andrew J. Lees,et al.  Treatment of Parkinson's disease: levodopa as the first choice , 2002, Journal of Neurology.

[25]  J. Jankovic,et al.  Variable expression of Parkinson's disease , 1990, Neurology.

[26]  P. Riederer,et al.  Distinction between benign and malignant type of parkinson's disease , 1979, Clinical Neurology and Neurosurgery.

[27]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[28]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[29]  S. Fahn Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[30]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .